Conversation with The Cancer Letter Conti: Don’t Count on an 80% Price Drop From the Launch of Neupogen’s Biosimilar February 06, 2015Vol.41 No.05By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Kramer: Our Cancer Risk is not Written in the Stars January 16, 2015Vol.41 No.02By Matthew Bin Han Ong
Conversation with The Cancer Letter Is Republican Control Better Than Two-Party Stalemate? December 19, 2014Vol.40 No.47By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Demetri: Morcellation Worsens Outcomes In Patients with Undiagnosed Cancers November 21, 2014Vol.40 No.44By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Einhorn: “I Still Harbor Hope For Similar Success Stories” October 24, 2014Vol.40 No.40By Matthew Bin Han Ong
Conversation with The Cancer LetterFree IU’s Loehrer Discusses “Business Decision” to Close Bloomington Proton Beam Center October 17, 2014Vol.40 No.39By Matthew Bin Han Ong
Conversation with The Cancer Letter “These are Life-Saving Drugs. I’m Not Going To Stop Treating Patients, Right?” October 03, 2014Vol.40 No.37By Paul Goldberg
Conversation with The Cancer Letter Pat White: NIH Funding “Our Only Concern” September 26, 2014Vol.40 No.36By Paul Goldberg
Conversation with The Cancer Letter Daniel Hayes Leads Tour of Caris Website August 08, 2014Vol.40 No.32By Paul Goldberg
Conversation with The Cancer LetterFree Bertagnolli: Why Brigham Stopped Making Morcellation Available Outside of a Registry Trial July 03, 2014Vol.40 No.27By Matthew Bin Han Ong
